Potential Efficacy of Citicoline as Adjunct Therapy in Treatment of Cerebral Malaria

8Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Cerebral malaria (CM) is characterized by a dysregulated immune response that results in endothelial membrane destabilization and increased microparticle (MP) production. Citicoline (CTC) is a membrane stabilizer used for the treatment of neurological disorders. We evaluated the efficacy of CTC as adjunct therapy to aid recovery from experimental CM. We show that CTC reduces MP production in vitro; in combination with artesunate in vivo, confers partial protection against CM; and prolongs survival. © 2014, American Society for Microbiology. All Rights Reserved.

Cite

CITATION STYLE

APA

El-Assaad, F., Combes, V., Raymond Grau, G. E., & Jamboua, R. (2014). Potential Efficacy of Citicoline as Adjunct Therapy in Treatment of Cerebral Malaria. Antimicrobial Agents and Chemotherapy, 58(1), 602–605. https://doi.org/10.1128/AAC.02591-12

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free